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Objectives: The pharmacokinetics of macrolide antibiotics - erythromycin (ER), clarithromycin (CL), roxithromycin (RO), 
azithromycin (AZ), dirithromycin (DI) and the concentrations achieved in polymorphonuclear neutrophils (PMNs) and 
saliva were investigated. 
Methods: In a four-way crossover trial, 10 healthy volunteers received 1000 mg ER twice a day, 500 mg  CL twice a day, 
150 mg  RO twice a day and 500 m g  AZ every day over a period of 3 days. In a second trial, 10 healthy volunteers received 
500 m g  DI every day over a period of 5 days. Concentrations of these antibiotics were measured in  serum, urine, saliva 
and PMNs by high-performance liquid chromatography (HPLC) on days 1 and 3 in  the first trial and on days 1 and 5 in 
the second trial. 
Results: We found considerable differences in  the pharmacokinetics, not only in serum, but also in  PMNs and saliva. All 
substances except RO exhibited higher concentrations in PMNs than in serum, indicating excellent intraphagocytic 
distribution. In contrast, concentrations in  saliva were lower than those measured in serum, with the exception of AZ. 
ER is characterized by low serum concentrations and moderate concentrations in  saliva and PMNs. CL reached 
considerable concentrations in serum, saliva and PMNs. RO achieved the highest serum levels, but concentrations in 
saliva and in PMNs were below the detection limit. In contrast, AZ and DI yielded the lowest serum concentrations and 
the highest saliva and PMN concentrations. 
Conclusions: Our data emphasize the importance of tissue distribution, in  addition to  serum kinetics, in evaluating the 
pharmacokinetic profiles of antibiotics. 
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INTRODUCTION 
Macrolide antibiotics have been available, and used 
clinically, since 1952, with erythromycin (ER) the most 
widely used agent of this class. Structurally, these 
antibiotics are characterized by a macrocyclic lactone 
ring linked glycosydically to amino glucose and 
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nitrogen free glucose moieties. The newer compounds 
differ from E R  in the size or substitution pattern of the 
lactone ring system, or in both these respects. They 
share a common antibacterial spectrum, with excellent 
activity against intracellular pathogens such as Legionella 
pneumoplzila, Mycoplasrna spp. and Chlamydia spp. [1-7]. 
ER base is characterized by poor water solubility and 
rapid inactivation by gastric acid, which result in widely 
varying bioavailability after oral administration [2]. 
Clarithromycin (CL), roxithromycin (RO), azithro- 
mycin (AZ) and dirithromycin (DI) have improved 
pharmacokinetic properties, especially high volumes of 
distribution and tissue concentrations, and improved 
acid stability [3,8,9]. In contrast to the other 
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macrolides, DI acts like a prodrug and is predominantly 
converted in vivo to erythromycylamine, which 
possesses similar antimicrobial activity [91. 
The objective of the two studies was the com- 
parison of pharmacokinetics and tissue concentrations 
of four new macrolides (CL, RO, AZ and DI) and E R  
after multiple-dose administration. Tissue concentra- 
tions were evaluated by measuring levels of antibiotics 
in polymorphonuclear neutrophils (PMNs) and saliva. 
PMNs are important cells of the human phagocytosis 
system and easy to isolate from the blood. Antibiotics 
accumulated in salivary gland tissue are excreted in 
saliva, which is easily collected. The levels of these 
substances in saliva reflect concentrations in the gland 
tissue [lo-? 21. 
MATERIALS AND METHODS 
Study design 
The first study adopted a randomized four-way cross- 
over multiple-dose design, and the second study a 
multiple-dose design. 
Volunteers 
Ten healthy subjects (five females, five males) without 
any known allergies to antibiotics or other medication 
participated in each of the trials. The mean age, body 
weight, body surface and creatinine clearance were 
similar for the volunteers in both studies (Table 1). 
Written informed consent was obtained. The studies 
were approved by the local ethics committee, according 
to German law. Female participants were tested for 
human chorionic gonadotropin (HCG) in urine to rule 
out pregnancy. All subjects had normal biochemical 
and hematologic profiles. None of the volunteers 
received any other antimicrobial agent during the 4 
weeks preceding the study or during the study period. 
Furthermore, alcohol, tea, coffee and other beverages 
containing caffeine, as well as any kind of medication, 
were not allowed during the study period. 
Antibiotics and dosage 
E R  was given as the stearate preparation (Erythromycin 
Table 1 Volunteers 
Trial 1 Trial 2 
Number 10" 1 0" 
Age (years) 27.9i4.7 30.2k5.3 
Weight (kg) 66.7f12.1 68.1flS.0 
Glomerular filtration rate 
(mL/min/1.73 m2) 95.tf15.4 90.2+_20.3 
"Five females, five males 
500 NEO@, lot number 44339VA, Abbott Ltd, 
Wiesbaden). RO was provided by Albert Roussel, 
Wiesbaden (lot number 165W0153), CL by Abbott 
Ltd, Wiesbaden (lot number 47051 TFB), AZ by Pfizer 
Ltd, Karlsruhe (lot number P 2705-04-001) and DI by 
Eli Lilly & Co, Indianapolis (lot number B0299-2B). 
During the first trial the subjects received 1000 mg E R  
twice a day, 150 mg RO twice a day, 500 mg CL twice 
a day and 500 rng AZ every day in four different 
courses, each over a period of 3 days, in a randoniized 
order. E R  and RO were given in the first and second 
courses, and CL and AZ in the third and fourth 
courses. The wash-out periods between the first three 
courses were 10 days; those between the third and the 
fourth courses 6 weeks. The prolonged period was 
chosen because of the longer half-life of AZ. 
During the second trial the subjects were given 
500 nig DI every day over a period of 5 days. 500 mg 
DI are equivalent to 440 mg erythromycylamine, 
which is the active compound. Concentrations are 
reported as DI. 
Samples 
Blood samples were taken on days 1 and 3 of dosing in 
the first study and on days 1 and 5 in the second study. 
Blood was collected before and 15, 30, 60 and 90 min 
and 2, 3, 4, 6, 8 and 12 h after dosage in both studies. 
In addition, blood samples were taken 24 h after the last 
administration of ER,  CL and RO, and 24 and 48 h 
after the last administration of DI and AZ, on days 3 
and 5 respectively. Serum was separated within 30 min 
after being taken and frozen at -80 "C. 
All volunteers provided pre-dose urine samples. 
After dosing, urine was collected on days 1 and 3 in the 
first trial and on days 1 and 5 in the second trial. The 
collection periods were between 0 and 6 and 6 and 12 h 
after administration of the antibiotics, except DI, with 
a third urine sampling between 12 and 24 h. O n  day 3 
of the first study and on day 5 of the second study, 
additional 12-24- and 24-48-h samples were obtained. 
Samples for assay were frozen at - 80 OC. 
Saliva and PMNs were collected on days 1 and 3 
in the first trial and on days 1 and 5 in the second trial. 
Samples were taken for the first study before and 1 and 
3 h after administration of E R  and before and 4 and 8 h 
after administration of CL, RO and AZ. O n  day 3 an 
additional sample was obtained 24 h after administra- 
tion of antibiotic except in the case of AZ, with two 
additional samples being taken after 24 and 48 h. 
During the second study, saliva and PMNs were 
sampled before and 4, 8 and 24 h after administration 
of DI. Samples for assay were frozen at -80OC. To 
produce saliva samples, the volunteers chewed a cotton 
wool swab for 60 s. Afterwards, approximately 0.7 mL 
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saliva was recovered from the swab by centrifugation at  
1560 'q for 10 niin. 
PMN preparation 
PMNs were separated from heparinized blood by 
gradient centrifugation using a separation medium 
(Ficoll-Paque@). After lysis and washing out of 
erythrocytes from the cell pellet, the PMN count was 
adjusted by dilution with HBSS (Hanks' balanced salts 
solution) to 2 X 107 cells/mL. The dilution volume was 
separated from the cell suspension by centrifugation. 
Lysis of PMNs was carried out with an ultrasonic 
homogenizer. 
Detection methods 
Serum, urine, saliva and PMNs were assayed for 
concentrations of the investigated antibiotics by high- 
performance liquid chromatography (HPLC). Since 
C L  undergoes considerable first-pass metabolism, the 
main metabolite, 14-hydroxyclarithroniycin (14-OH- 
CL), which also has antibacterial activity, was 
determined additionally. 
Table 2 Validation data of the HPLC methods for the 
investigated inacrolides in serum, PMNs and saliva 
Detection Precision 
limit between series Recovery 
("g/L) (CV'X) (0% 
El< 
Scrum 
PMNs 
Sallvd 
CL/14-OH-CL 
Scrum 
PMNs 
Sallvd 
RO 
Serum 
PMNs 
Saliva 
AZ 
Serum 
PMNs 
Saliva 
I l l '  
Serum 
PMNs 
Saliva 
0.1 
0.1 
0.04 
0.05 
0.05 
0.05 
0.14 
0.02 
0.004 
0.02 
0.02 
0.02 
0.043 
0.025 
0.036 
3.6-21.4' 
7.0-12.8 
N D  
5.3-8.0 
5.3-8.0 
5.3-8.0 
2.9-5.4 
4.8-10.6 
3.9-9.2 
4.8-12.5 
4.8-12.5 
4.8-12.5 
6.4-8. 0 
6.7-8.1 
6.5-9.1 
99 
03-100 
N D  
109-113 
109-113 
109-113 
80 -100 
93-103 
100-103 
98 
98 
98 
08-101 
104-1 05 
96-99 
"Erythroin).cylanline, 
'This high CV (coefficient of variation) was found only at low 
concentrations (<0.25 mg/L). 
ND=not determined. 
Erythrom ycin 
HPLC assays were carried out using a modification of 
published methods and an internal Abbott protocol 
[13, 141. CL was used as internal standard. The organic 
phase was evaporated in a vacuum concentrator. The 
residue was dissolved in mobile phase. E R  and CL were 
separated by reverse-phase chromatography and 
detected with an electrochemical detector. 
Roxithrom ycin 
HPLC assays were performed by using a modification 
of a method described by Demotes-Mainairde et al. 
[15]. Extraction of RO from serum, urine, cells and 
saliva was performed with butylmethylether. The RO 
was separated by reverse-phase chromatography and 
detected with an electrochemical detector. 
Clarithromycin and 14-hydroxy-clarithromycin 
Concentrations of CL and its metabolite 14-OH-CL 
were measured using the method described by Borner 
et al. [16]. 
Azithromycin 
HPLC assays were carried out using a modification of 
a method described by Shepard et al. [17]. After 
alkalinization of the samples, AZ was extracted with 
butylmethylether, and separated by reverse-phace 
chromatography; the detection wa? performed with an 
electrochemical detector. 
Dirithrom ycin 
Erythroniycylamine, which is the active compound of 
DI, was determined by reverse-phase HPLC and 
electrochemical detection after liquid/liquid extraction 
Validation data for the HPLC methods described 
L181. 
above are summarized in Table 2. 
Pharmacokinetic calculations and statistical evaluations 
Pharmacokinetic parameters were calculated for the 
first day assuming an open one-compartment model, 
and for the third day of the first trial and the fifth day 
of the second trial assuming an open two-compartment 
model. The decision to use a specific (mathematical) 
model was based on the Schwarz criterion. The models 
have been used to calculate T,,,,,, C,,,,, and t 1 /2  only; 
the majority of the pharmacokinetic parameters have 
been calculated 'non-compartmentally', i.e. the results 
do not depend on a particular assumption. All results 
were normalized to 70 kg body weight; clearance 
values were calculated for a body surface of 1.73 m2. 
Wilcoxon's rank test was used for statistical analysis. P 
values < 0.05 were considered significant. 
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Table 3 Pharmacokinetic results: arithmetic means and standard deviations 
CW t l /za AUCtot v d  C1," Ue: 
(mg/L) (h) (mg X h/L) (L/kg) (mL/min/1.73 m3) (96 of oral dose) 
Day 1 
ER 1.51t0.6 2.9f 0.8 5.4k3.1 12.916.4 37.6f17.6 0.73f0.3 
CL 2.1k0.7 3.9f1.0 15.3k4.8 3.7k0.4 139.6f42.6 20.6f4.3 
14-OH-CL 0.81+0.2 9.7k3.1 11.8k4.7 6.9k1.6 119.0k78.7 6.9fl .Y 
AZ 0.43k0.2 2.8f1.0 1.6k0.61 29.2k8.0 273.5f82.6 4.021.2 
DI 0.3Yk0.3 19.226.5' 2.221.0 48.6k24.4' 60.6k18.4 1.6f0.9 
Day 3 
ER 1.3f0.5 7.Yf3.4 5.2k2.78 10.8k3.4 45.9k36.0 1.8k0.7 
CL 2.3f1.0 7.8f2.5 27.9f12.4 3.211.5 158.6k77.3 52.0k10.7 
14-OH-CL 0.5120.23 10.51t2.3 9.125.3 1Y.3k16.3 246.4f195.8 26.2k5.4 
KO 4.31t2.6 11.8f0.5 47.3k20.5 0.87+0.63 10.7f4.4 15.014.7 
AZ 0.59f0.4 10.8k3.0 2.6f0.9 36.Yk7.1 296.6k80.6 10.9k2.4 
DAY 5 
DI 0.50k0.21 19.2k6.5 3.2k1.6 48.6f24.4' 65.1 f14.7 5.4k1.6 
~~______  
'Day 1: first half-life (a-phase). Day 3/5: terminal half-life (P-phase). 
'Day 1: Urinary recovery over 12 h. Day 3/5: Urinary recovery over 48 h. 
'Common analysis of data on all days 
Pharmacokinetic parameters 
The pharmacokinetic results are summarized in Table 
3. Comparison of the data on day 1 and at steady state 
(day 3 in study 1, day 5 in study 2) revealed some 
significant differences ( p  < 0.05). After the last dosing a 
rise in urinary recovery (U,,)and half-life ( t112)  was 
observed for all substances (for DI a common half-life 
was calculated analyzing all the data from all days). An 
increase of the area under the curve (AUC) for CL, AZ, 
DI, and of the peak serum concentration (C,,,,) for DI, 
occurred after multiple dosing. An explanation of these 
changes could be the longer period of urine and serum 
collection at  steady state, compared with the first day 
of dosing. 
The pharmacokinetics at  steady state were as 
follows: C,,,, and AUC were highest for RO with 
4.3 mg/L and 47.3 mgxh/L respectively, followed by 
CL with 2.3 mg/L and 27.9 m g x  h/L respectively (and 
0.51 mg/L and 9.1 mgxh/L for the metabolite 14- 
OH-CL). E R  was characterized by low C,,,,, and AUC 
values (1.3 mg/L and 5.17 mgXh/L respectively), 
while AZ and DI exhibited by far the lowest values 
for these parameters (0.59 mg/L and 2.59 m g x  h/L, 
and 0.5 mg/L and 3.2 mgxh/L, respectively). The 
terminal half-life of DI showed the highest value 
(19.2 h), followedbyRO (11.7 h) ,AZ (10.7 h) andCL 
and its metabolite (7.8 and 10.5 h, respectively). The 
 TI,^ of E R  was calculated as 7.9 h. DI and AZ were 
characterized by the largest volumes of distribution 
(I/d), at 48.6 and 36.9 L/kg, respectively, indicating 
high tissue concentrations. In contrast, the lowest vd of 
0.87 L/kg was calculated for RO. CL and E R  yielded 
the moderate I/d values of 3.2 and 10.8 L/kg, while a 
vd of 19.3 L/kg was measured for 14-OH-CL. Urinary 
recoveries (0-48 h) were highest for CL and 14-OH- 
CL (52% and 26%, respectively, of the given dose), 
followed by RO (15%), AZ (10.9%), DI (5.35%) and 
E R  (4.2%). Renal clearance (clren) varied considerably 
among the investigated macrolides. RO exhibited the 
lowest and AZ the highest value, at 10.7 and 
296.6 mL/min/1.73 m3, respectively. 
Macrolide concentrations in PMNs 
Macrolide concentrations in PMNs are shown in 
Table 4. Accumulation factors corresponding to the 
ratio of the cellular concentration in PMNs to the 
extracellular concentration in serum (= C/E) are 
given in Table 5. 
Concentrations for all substances except RO 
exceeded by far those in serum; therefore, the 
accumulation factors were considerably greater than 1 
and increased significantly at  steady state (day 3 in study 
1, day 5 in study 2). This increase could be due to tissue 
accumulation after multiple dosing. AZ exhibited the 
highest concentrations in PMNs: 15.9 and 13.1 mg/L 
after 4 and 8 h of application on day 1, and 39.3, 41.6, 
28.7 and 24.8 mg/L after 4, 8, 24 and 48 h on day 3, 
respectively. Levels of DI were 3.81, 3.81 and 
2.85 mg/L after 4 , 8  and 24 h on day 1 and 13.31,13.38 
and 10.47 mg/l after 4, 8 and 24 h on day 5. CL 
achieved PMN concentrations of 5.78 and 4.82 mg/L 
on day 1 and 13.9 and 9.42 mg/L on day 3 after 4 and 
8 h of administration. Values for 14-OH-CL were 3.98 
and 3.39 mg/L on day 1, and 7.99 and 6.28 mg/L on 
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Table 4 Macrolide concentrations in PMNs (nig/L): 
Arithmetic nieaiis and ctandard deviations 
Substance Tmie after application Day 1 
(h) 
7iial I 
ER 1 2.921.6 
3 1.9k0.8 
24 ND 
CL 4 -5.8 f 2 . 5  
8 4.8f5.4 
24 ND 
14-OH-CL 4 4.0k1.9 
8 3.421.3 
24 N 13 
I10 4 BDL 
8 BDL 
24 ND 
AZ 4 15.9t5.l 
8 13.1-t 4.6 
24 ND 
48 ND 
Yi ia l  2 
DI 4 3.8k2.3 
8 3.8k2.4 
24 2.81-1.4 
Day 3a 
6.1 k0.8 
6.6k1.1 
4.0k1.6 
13.9k8.4 
9.4k3.2 
BDL 
8.0k3.6 
6.3 k 2.2 
UDL 
BDL 
BDL 
BDL 
39.3k12.9 
41.6k1 1.8 
28.7k11.9 
24.8k8.8 
13.3k4.8 
13.4k4.2 
10.5k2.5 
All values increased significantly (p<0.01) at day 3/5 versus day 1 
(except the 8-11 values of 14-OH-CL). 
Nl)=not donc. 
BDL=below detection limit. 
,'Day 5/Trial 2. 
day 3, after 4 and 8 h. Concentrations of CL and 14- 
OH-CL 24 h after dosing on day 3 were below the 
detection limit of the HPLC method. Levels of E R  in 
PMNs were 2.9 and 1.9 mg/L after 1 and 3 h on day 
1, and 6.07, 6.58 and 3.99 mg/L after 1, 3 and 24 h o n  
day 3. In contrast the concentrations o f R O  were below 
the detection limit of the HPLC method in all PMN 
samples. The highest accumulation factor was 
calculated for AZ at 859, followed by DI at 106, 14- 
OH-CL at  10.2, CL at 6.5 and E R  at 6.2, at  steady 
state. 
Macrolide concentrations in saliva 
Macrolide concentrations in saliva are shown in Table 
6. The levels of all substances except AZ were below 
those measured in serum. An increase in these values 
was observed at steady state; only the metabolite 14- 
OH-CL and the 1-h value for E R  did not show any 
differences after first and last dosings. 
The mean concentrations of CL were 1.06 and 
0.48 mg/L 4 and 8 h after administration on day 1, and 
1.87, 0.83 and 0.25 mg/L after 4, 8 and 24 h on day 3. 
Values for 14-OH-CL were 0.94 and 0.52 mg/L after 
4 and 8 h on day 1, and 0.84, 0.45 and 0.19 mg/L after 
4, 8 and 24 h at  steady state. AZ achieved saliva 
concentrations of 0.59 and 0.31 mg/L after 4 and 8 h 
Table 5 Accuniulatioii factors for macrolides in  PMNs 
(C/E): Arithmetic means and standard deviations 
Substance Time after application Day 1 Day 32 
(h) 
?'rial 1 
EK 
CL 
14-OH-C:L 
KO 
AZ 
Trial 2 
DI 
1 
3 
24 
4 
8 
24 
4 
8 
24 
4 
8 
24 
4 
8 
24 
48 
4 
8 
24 
2.451.9 
3.7 k2.0 
NI) 
3.3k0.8 
5.6k6.6 
ND 
4.5k1.7 
8 . x i 7  .o 
ND 
N A  
NA 
N D  
85.5f36.8 
181k43.6 
ND 
N D 
21.7k9.3 
58.4k27.2 
73.41-37.9 
3.6fl .5 
0.2k2. h 
N A  
6.0 k 2.9 
6.5k2.0 
NA 
10.2f3.1 
9.6k2.3 
NA 
NA 
NA 
NA 
1SOf58 
369k86 
437+173 
859k544 
37.3k14.1 
97.3f5.5 
106.6227.4 
ND=not done. 
NA=not applicable 
"Day 5/Trial 2. 
Table 6 Macrolide concentrations in saliva (mg/L): 
Arithmetic means and standard deviations 
Substance Time after application Day 1 
(h) 
Trial 1 
ER 1 0.2020.1 
3 O.lOk0.04 
24 ND 
CL 4 1.06k0.7 
8 0.4820.2 
24 ND 
14-OH-CL 4 0.94kn.7 
8 0.52kO.2 
24 ND 
RO 4 BDL 
8 BDL 
24 ND 
AZ 
Trial 
DI 
4 0.59kO.4 
8 0.31+0.1 
24 ND 
2 
4 0.09If-0.08 
8 0.052O.05 
24 0.03k0.02 
flay 3a 
0.3 1 kO.1 
0.19f0.07 
UDL 
1.87k1.3 
0.83k0..5 
9.25k0.1 
0.84k0.6 
0.45M.3 
0.19+0. 1 
BDL 
BDL 
BDL 
1.61i1.2 
0.67 If-0.5 
0.42k0.2 
0.3 1 k0. 1 6 
0.1720.05 
0.1OfO.05 
All measurable values increased significantly @ < 0.01-0.(J05) at day 
3/5 versus day 1 (except the 1-h values of ER and all value$ of 14- 
OH-CL). 
ND=not  done. 
Bl>L=below detection limit. 
"Day S/Trial 2. 
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Figure 1 Maximal macrolide concentrations in serum, PMNs and saliva at steady state (mg/L): Arithmetic means and 
standard deviations. 
on day 1, and 1.61, 0.67 and 0.42 mg/L after 4, 8 and 
24 h on day 3. The levels of E R  were 0.20 and 
0.10 mg/L and 0.31 and 0.19 mg/L after 1 and 3 h of 
administration on days 1 and 3, respectively. O n  day 3, 
concentrations of E R  were below the detection limit 
24 h after application. DI was characterized by low 
values with 0.09, 0.05 and 0.03 mg/L on day 1 and 
0.31, 0.17 and 0.10 mg/L on day 5, after 4, 8 and 24 h 
of application. Levels of RO were below the detection 
limit of the HPLC method in almost all saliva samples. 
The maximal macrolide concentrations in serum, 
PMNs and saliva are shown in Figure 1. 
DISCUSSION 
Macrolide antibiotics are of significant interest and 
importance since intracellular infections are increasing 
with higher numbers of immunocompromised hosts. 
In these two studies the pharmacokinetics of ER,  CL, 
RO, AZ and DI and the concentrations achieved in 
PMNs and saliva were analyzed. 
E R  showed low serum concentrations and 
moderate concentrations in PMNs and saliva. Since E R  
is characterized by poor water solubility and rapid 
inactivation by gastric acid, the bioavailability of this 
compound is unpredictable. In the literature C,,, 
values after dosing with 500 mg E R  stearate have 
been given as 1.23 [lo], 0.5 and 2.9 mg/L [19]. 
Concentrations of E R  in PMNs exceeded those in 
serum, with a peak level of 6.58 mg/L 3 h after 
application at  steady state, corresponding to an 
accumulation factor of 6.2. Studies in vitro with 14C- 
labeled E R  demonstrated accumulation factors of 9.7 
[20], 6.6 [21] and 8.0 [22] in PMNs compared with 
extracellular fluid. Studies in vivo in volunteers are not 
available. Concentrations in saliva of E R  were below 
those measured in serum. A maximal value of 
0.31 mg/L was detected at  steady state 1 h after 
administration, and an accumulation factor of 0.17 was 
calculated. These results are in good agreement with 
other studies. Touminen found an accumulation factor 
for saliva between 0.12 and 0.20 compared with serum 
levels after administration of 500 mg E R  acistrate 1231. 
In another study 0.71 mg/L E R  was measured in saliva 
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2 h after adniinistration of 500 nig E R  propioiiate 1101. 
In contrast Stephen et a1 could not detect E R  in saliva 
after administration of 2 X 250 nig E R  estolate [ 111. 
CL and 14-OH-CL were characterized by 
considerable concentrations in serum and in PMNs, 
while d i v a  levels were moderate. Peak ser~nii 
concentrations after the first dose of 500 nig C L  were 
2.1 and 0.81 mg/L for the original substance and the 
metabolite, respectively. Between days 1 and 3 there 
was no significant change in this parameter. In contrast, 
AUC values rose significantly from 15.3 mgX h/L after 
the first dosing to 27.9 mgXh/L after the last dosing. 
An explanation of this increase could be the longer 
serum collection period at day 3. Pharniacokinetic data 
published in the literature are in good agreement with 
these results. Neu measured C,,,,, values of 2.41 and 
0.66 mg/L after administration of 500 mg CL and 14- 
OH-CL respectively [24]. Another study reported a 
peak serum concentration and an AUC value of 
2.14 mg/L and 17.4 mgxh/L,  respectively after 
administration of 400 nig CL 1251. In a multiple-dose 
study, CL was administered in a dose of 500 nig every 
12 h for a period of 3.5 days [4]. After the first dose 
peak serum concentrations varied between 1.77 and 
1.89 mg/L for C L  and 0.67 and 0.8 mg/L for the 
metabolite; at  steady state these values were between 
2.4 and 3.5 nig/L and 0.7 and 0.8 mg/L, respectively. 
This significant increase in serum levels afier multiple 
dosing was in contrast to our data. 
Levels of CL and its metabolite in PMNs exceeded 
those in serum. In PMNs the highest concentrations of 
CL and its metabolite were measured at steady state 
after 4 h of dosing at 13.9 and 6.28 mg/L. The highest 
accumulation factors were 6.45 for CL and 10.2 for 14- 
OH-CL after 8 and 4 h of administration, respectively. 
N o  other data on in vivo studies have been published. 
PMN concentrations of CL were investigated in vitro 
by Ishiguro et a1 1211. After incubation of PMNs for 30 
min with 10 mg/L CL, the intracellular accumulation 
factor reached 16.4. Saliva concentrations of CL and its 
metabolite were highest at  steady state 4 h after dosing 
with 1.87 and 0.84 mg/L, respectively. The accuniu- 
lation factor reached maximal values of 0.89 and 0.88 
a t  steady state 24 h after administration, indicating 
lower saliva than serum levels. The results of another 
study included an accumulation factor for CL in saliva 
of 0.5 and 1.9 after single doses of 150 and 400 mg, 
respectively [4]. In serum and saliva the metabolite 14- 
OH-CL was not reported. 
With RO the highest serum concentrations of all 
were found. C,,,,, values reached 5.3 and 4.3 mg/L after 
first and last dosing, respectively. The data are in 
agreement with other studies. Nilson found maximal 
serum concentrations between 5.4 and 7.9 mg/L after 
giving a single dose of 150 mg 1x0 [19]. In  a multiple- 
dose study, 150 mg KO was administered every 12 h 
over a period of 11 days [26]. In contrast to our results, 
there was a rise of C,,,,, from 7.9 to 9.3 mg/L after the 
first and the last dose, respectively. Levels of KO in 
PMNs and saliva were below the detection limits of the 
HPLC method. The low volume of distribution 
derived from our pharmacokinetic calculations also 
indicated relatively low tissue concentrations of this 
compound. 
These data are in contrast to results obtained in 
several in vitro studies, where PMN concentrations 
were investigated with "C-labeled RO. Carlier et al. 
found an accumulation factor of 14 after 30 niin of 
incubation ofhuman PMNs with 14C-labeled KO [22]; 
Ishiguro et a1 calculated an accumulation factor of 21.9 
after an incubation period of 60 min [21]. The lower 
PMN values in our in vivo study might be due to an 
efflux of the antibiotic from the intracellular space into 
the extracellular medium, as reported by Puri and 
Lassniann [26]. Concentrations of KO in saliva were 
investigated by Sorgel et a1 [27]. After a single dose of 
150 mg RO to four volunteers, the highest con- 
centration was 0.3 mg/L. 
AZ and DI are different from the other macrolides 
in being characterized by the lowest serum levels and 
longest terminal half-lives. At steady state, peak serum 
concentrations reached 0.59 and 0.50 mg/L for AZ and 
DI, respectively; half-lives were calculated as 10.8 h for 
AZ and 19.2 h for DI. Published pharmacokinetic 
studies have reported similar serum levels but longer 
half-lives. After administration of 500 ing AZ, C,,,,L, 
values of 0.41 and 0.40 mg/L were achieved in two 
other studies 125, 281. A terminal half-life of 41 h was 
measured when AZ was given in a dose of 500 mg 
intravenously [25]. After administration of 500 mg DI 
to volunteers, a C,,,,, value of 0.20 mg/L and a terminal 
half-life of 42 h have been reported [29]. In contrast to 
their low serum levels, these antibiotics are 
characterized by high tissue concentrations. The 
highest concentrations in PMNs were found 8 h after 
dosage at  steady state, at 41.6 mg/L for A Z  and 
13.4 mg/L for DI. Maximal accumulation factors of 
859 (AZ) and 106 (DI) were calculated at steady state, 
48 and 24 h after dosing. In several in vitro studies 
PMNs were incubated with "C-labeled AZ and DI. 
After an incubation period of 40 niin with 4 mg/L of 
AZ, an accumulation factor of 298 was calculated [30]. 
Gladue found an accumulation factor of 79 after 2 h of 
incubation with a dose of 10 mg/L AZ [31]. For DI an 
accumulation factor of 35 has been reported after an 
incubation period of 2 h with 21 mg/L [32]. In vivo 
studies obtained similar results. In rats and dogs tissue 
concentrations of AZ were more than 100 times 
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higher than serum levels [33]. Concentrations of 
erythromycylanline (the active metabolite of DI) in 
human lung tissue were about 20 to 40 times greater 
than the simultaneouc values in plasma 12 or 24 h after 
administration of 250- or 500-mg tablets [34]. 
Saliva concentrations reached peak values at  steady 
state 4 h after dosing with 0.67 rng/L for AZ and 
0.31 mg/L for DI. The highest accumulation factor of 
AZ was calculated 24 h after dosing at steady state, with 
a value of 6.38. DI exhibited lower concentrations in 
saliva than in serum, corresponding to accumulation 
factors below 1. There are no other published data 
available on concentrations of these macrolides in saliva. 
In conclusion, we found considerable differences 
both in pharmacokinetics and in PMN and saliva 
concentrations with the investigated macrolides. These 
differences may be an expression of different lipid 
solubilities, usage of different channels or carrier 
systems to enter into the cells or different forms of 
trapping inside cell organelles; in addition, different 
mechanisms of efflux from the cells have been reported 
1353. 
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